Adamis Pharmaceuticals Corporation trades as part of the healthcare sector and drug manufacturers industry. The company CEO is Dennis J. Carlo. Adamis Pharmaceuticals Corp is a specialty biopharmaceutical company that develops and commercializes products in the therapeutic areas of respiratory disease and allergy. Its products include Epinephrine Injection PFS syringe, APC000, APC-2000, and APC-5000.
Previous Intraday Performance:
The ADMP shares had a previous change of -0.66% which opened at 1.53 and closed at 1.50. It moved to an intraday high of 1.60 and a low of 1.49.
SeekingAlpha: ARRY, DY, QD and DQ among notable midday movers
Historical Performance:
Over the last five trading days, ADMP shares returned -17.58% and in the past 30 trading days it returned -25.00%. Over three months, it changed -52.08%. In one year it has changed -65.52% and within that year its 52 week high was 5.10 and its 52 week low was 1.49. ADMP stock is 0.67% above its 52 week low.
Our calculations result in a 200 day moving average of 2.66 and a 50 day moving average of 2.01. Right now, ADMP stock is trading -43.69% below its 200 day moving average and may not be a great opportunity to buy as it may continue to trend down.
SeekingAlpha: ARRY, DY, QD and DQ among notable midday movers
Liquidity:
The company has a market cap of $71.2m with 47.4m shares outstanding and a float of 39.1m shares. Trading volume was 474,983 shares and has experienced an average volume of 344,294 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.
Earnings:
The last annual reported EPS for Adamis Pharmaceuticals Corporation was -1.01 which ended on 31st of December 2018. Based on 2 analyst estimates, the consensus EPS for the next quarter is -0.15.
Below was the last reported quarterly diluted earnings per share:
1st | Qtr 2019 | -0.19 |
---|---|---|
4th | Qtr 2018 | -0.28 |
3rd | Qtr 2018 | -0.21 |
2nd | Qtr 2018 | -0.29 |
1st | Qtr 2018 | -0.23 |
The long-term trend of the EPS is a vital number as it helps understand the future potential of Adamis Pharmaceuticals Corporation; the EPS growth rate, as it is typically called, is usually expressed as a percentage, which at this time is hard to estimate, but revenue growth has been -7.60% over the last twelve months.
Indicators Also to Watch:
Based on the latest filings, there is 22.10% of institutional ownership.
The beta was calculated to be 1.50.
SeekingAlpha: Advanced Emissions Solutions Inc. (ADES) CEO Heath Sampson on Q1 2019 Results – Earnings Call Transcript
Fundamental Numbers:
Based on last reported financials, the company’s return on equity is -114.67%, return on assets is -87.04%, price-to-sales is 4.26 and price-to-book is 1.79.
Company Score Card:
Results are out of six:
5 : Growth Expectations Result
3 : Financial Safety Result
0 : Past Performance Result
1 : Valuation Result
0 : Dividend Safety Result
2 : Overall Result
Related Tags: Adamis Pharmaceuticals Corporation, ADMP, Drug Manufacturers, Healthcare